NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
The prospectus regarding the rights issue in ChromoGenics AB (publ) has been approved and registered with the Swedish Financial Supervisory Authority and is available (in Swedish only) on the ChromoGenics website, www.chromogenics.com/sv/investerare , and on Evli Bank's website, www.evli.com .
The rights issue in summary
- Anyone registered as a shareholder in ChromoGenics on the record day 4 January, has a pre-emptive right to subscribe for units in the Rights Issue, where one (1) existing share entitles to one (1) unit right.
- One (1) unit right entitles to subscription for one (1) unit, consisting of one (1) share at a subscription price of SEK 1.75 per share and one (1) warrant against no consideration.
- Each warrant entitles to subscription for one (1) new share in ChromoGenics at a price of 3.50 SEK per share (exercise price) during the period 10 to 31 January 2020.
- Upon full subscription in the Rights Issue, the Company will raise approximately MSEK 40.6 before transaction costs.
- Subscription period for Units is 8 – 22 January 2018.
- Trading in unit rights takes place during 8 – 18 January 2018.
- The Rights Issue is guaranteed via subscription and guarantee commitments up to approximately 81.3 percent of the maximum amount of MSEK 40.6, corresponding to approximately MSEK 33.0.
Directly registered shareholders will be sent an information leaflet and an issue report from Euroclear with a pre-printed payment slip. Nominee registered shareholders will not receive any issue report. Subscription and payment shall be made in accordance with the instructions of the respective bank or other trustee.
The outcome of the rights issue will be published by press release, which is expected to take place on January 26, 2018.
Financial and legal advisors regarding the Rights Issue
Evli Bank Plc. is financial advisor and Advokatfirman Lindahl KB is legal advisor to ChromoGenics in connection with the issue.
For more information, please contact
Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
+46 (0)18 430 04 30
Certified Adviser: G&W Fondkommission
This information constitutes such information that ChromoGenics AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted by the above-mentioned contact persons for publication on 5 January 2018, at 8:30 a.m. CET.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in ChromoGenics. Any invitation to the persons concerned to subscribe for shares in ChromoGenics will only be made through the prospectus referred to in this press release.
This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to those required under Swedish laws and regulations. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No shares have been or will be registered under the U.S. Securities Act of 1933, as amended (“Securities Act”), or securities legislation in any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.
This press release may contain forward-looking statements which reflect ChromoGenics's current view on future events and financial and operational development. The words “intend”, “estimate”, “expect”, “may”, “plan”, “anticipate” or similar expressions regarding indications or predictions of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Although ChromoGenics believes that these statements are based on reasonable assumptions and expectations, ChromoGenics cannot give any assurances that such statements will materialize. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties, and the outcome could differ materially from the information set out in the forward-looking statements.
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight® provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser. www.chromogenics.com
Powered by WPeMatico